N1-pyrazolospiroketone acetyl-coa carboxylase inhibitor

Abstract

The invention provides a compound of Formula (I)wherein R1 is (CrC6)alkyl, (C3-C7)cycloalkyl, tetrahydrofuranyl or oxetanyl; wherein said (C^-Ce) alkyl is optionally substituted with 1 to 2 substituents independently selected from (C1C3)alkoxy, hydroxy, fluoro, phenyl, tetrahydrOfuranyf or oxetanyl; R2 is hydrogen, halo, (Cj-alkyl, or cyano; R3 are each independently hydrogen or (C1-C3) alkyl R4 is a (C6-C10)aryl, 5 to 12 membered het eroaryl Or 8 to 12 membered fused heterocydicaryl; wherein said (C6-C10)aryl, 5 to 12 membered heteroaryl or 8 to 12 membered fused heterocyclicaryl are each optionally substituted with one to three substituents independently selected from (Ct-C3)alkyl, (CrC3) alkoxy, ^halo, amino» (CrC3)alkylamino, di(C1-C3)alkylamino, hydroxy, cyano, amido, phenyl, 5 to 6 membered heteroaryl or .5 to 6 membered heterocyc|yl; pharmaceutical composition thereof for treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.